Interplay among viral antigens, cellular pathways and tumor microenvironment in the pathogenesis of EBV-driven lymphomas

Seminars in Cancer Biology

Volumn 23, Issue 6 Part A, 2013, Pages 441-456

  Dolcetti, Riccardo ^a   Dal Col, Jessica ^a   Martorelli, Debora ^a   Carbone, Antonino ^a   Klein, Eva ^b  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Epstein Barr virus; Latency; Lymphomas; Lytic replication; Signaling pathways

Indexed keywords

EBER 1 PROTEIN; EBER 2 PROTEIN; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN 2; EPSTEIN BARR VIRUS ANTIGEN 3; LMP 1 PROTEIN; LMP 2 PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS PROTEIN;

ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; B CELL LYMPHOMA; BURKITT LYMPHOMA; CARCINOGENESIS; CELL ACTIVATION; CELL TRANSFORMATION; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; EBER 1 GENE; EBER 2 GENE; EBNA 1 GENE; EBNA 2 GENE; EBNA 3 GENE; ELDERLY CARE; ENTEROPATHY T CELL LYMPHOMA; EPSTEIN BARR VIRUS; GENE FUNCTION; GENE IDENTIFICATION; HEPATOSPENIC T CELL LYMPHOMA; HISTOPATHOLOGY; HIV ASSOCIATED LYMPHOPROLIFERATIVE DISEASE; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNE RESPONSE; LARGE CELL LYMPHOMA; LMP 1 GENE; LMP 2 GENE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NK T CELL LYMPHOMA; NONHUMAN; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; TUMOR MICROENVIRONMENT; VIRUS ETIOLOGY; VIRUS GENE; VIRUS IDENTIFICATION;

EPSTEIN-BARR VIRUS; LATENCY; LYMPHOMAS; LYTIC REPLICATION; SIGNALING PATHWAYS;

ANTIGENS, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA; LYMPHOMA, AIDS-RELATED; TUMOR MICROENVIRONMENT; VIRUS LATENCY;

EID: 84887613052     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.07.005     Document Type: Review

References (199)

1. Cohen J.I. Epstein-Barr virus infection. New England Journal of Medicine 2000, 343(August (7)):481-492.
2. Babcock G.J., Decker L.L., Volk M., Thorley-Lawson D.A. EBV persistence in memory B cells in vivo. Immunity 1998, 9(September (3)):395-404.
3. Miyashita E.M., Yang B., Babcock G.J., Thorley-Lawson D.A. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. Journal of Virology 1997, 71(July (7)):4882-4891.
4. Babcock G.J., Hochberg D., Thorley-Lawson A.D. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 2000, 13(October (4)):497-506.
5. Thorley-Lawson D.A. Epstein-Barr virus: exploiting the immune system. Nature Reviews Immunology 2001, 1(October (1)):75-82.
6. Klein E., Nagy N., Rasul A.E. EBV genome carrying B lymphocytes that express the nuclear protein EBNA-2 but not LMP-1: type IIb latency. Oncoimmunology 2013, 2(February (2)):e23035.
7. Yajima M., Kanda T., Takada K. Critical role of Epstein-Barr Virus (EBV)-encoded RNA in efficient EBV-induced B-lymphocyte growth transformation. Journal of Virology 2005, 79(April (7)):4298-4307.
8. Carbone A., Gloghini A., Dotti G. EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 2008, 13(May (5)):577-585.
9. Magrath I. Epidemiology: clues to the pathogenesis of Burkitt lymphoma. British Journal of Haematology 2012, 156(March (6)):744-756.
10. Jaffe E.S. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology. American Society of Hematology. Education Program 2009, 2009:523-531.
11. Swerdlow S., Campo E., Harris N., Jaffe E., Pileri S.A., Stein H., et al. World Health Organization classification of tumors, pathology and genetics of tumours of Hematopoietic and Lymphoid Tissues 2008, International Agency of Research on Cancer (IARC).
12. Townsend W., Linch D. Hodgkin's lymphoma in adults. Lancet 2012, 380(September (9844)):836-847.
13. Flavell K.J., Murray P.G. Hodgkin's disease and the Epstein-Barr virus. Molecular Pathology 2000, 53(October (5)):262-269.
14. Hjalgrim H., Smedby K.E., Rostgaard K., Molin D., Hamilton-Dutoit S., Chang E.T., et al. Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Research 2007, 67(March (5)):2382-2388.
15. Khalidi H.S., Lones M.A., Zhou Y., Weiss L.M., Medeiros L.J. Detection of Epstein-Barr virus in the L & H cells of nodular lymphocyte predominance Hodgkin's disease: report of a case documented by immunohistochemical, in situ hybridization, and polymerase chain reaction methods. American Journal of Clinical Pathology 1997, 108(December (6)):687-692.
16. McKhann C.F. Primary malignancy in patients undergoing immunosuppression for renal transplantation. Transplantation 1969, 8(August (2)):209-212.
17. Penn I., Hammond W., Brettschneider L., Starzl T.E. Malignant lymphomas in transplantation patients. Transplantation Proceedings 1969, 1(March (1)):106-112.
18. Landgren O., Gilbert E.S., Rizzo J.D., Socie G., Banks P.M., Sobocinski K.A., et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009, 113(May (20)):4992-5001.
19. Gross T.G., Savoldo B., Punnett A. Posttransplant lymphoproliferative diseases. Pediatric Clinics of North America 2010, 57(April (2)):481-503.
20. Thompson M.P., Kurzrock R. Epstein-Barr virus and cancer. Clinical Cancer Research 2004, 10(February (3)):803-821.
21. Davis J.E., Moss D.J. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies. Tissue Antigens 2004, 63(April (4)):285-292.
22. Raphael M., Borisch B., Jaffe E.S. Lymphomas associated with infection by the human immune deficiency virus (HIV). World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue Ed. by E.S. Jaffe, N.L. Harris, H. Stein, and J.W. Varidman 2001, 260-263. IARC Press, Lyon.
23. Cesarman E., Chang Y., Moore P.S., Said J.W., Knowles D.M. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. New England Journal of Medicine 1995, 332(May (18)):1186-1191.
24. Delecluse H.J., Feederle R., O'Sullivan B., Taniere P. Epstein Barr virus-associated tumours: an update for the attention of the working pathologist. Journal of Clinical Pathology 2007, 60(December (12)):1358-1364.
25. Carbone A., Gaidano G., Gloghini A., Ferlito A., Rinaldo A., Stein H. AIDS-related plasmablastic lymphomas of the oral cavity and jaws: a diagnostic dilemma. Annals of Otology, Rhinology and Laryngology 1999, 108(January (1)):95-99.
26. Oyama T., Yamamoto K., Asano N., Oshiro A., Suzuki R., Kagami Y., et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clinical Cancer Research 2007, 13(September (17)):5124-5132.
27. Adam P., Bonzheim I., Fend F., Quintanilla-Martinez L. Epstein-Barr virus-positive diffuse large B-cell lymphomas of the elderly. Advances in Anatomic Pathology 2011, 18(September (5)):349-355.
28. Wong H.H., Wang J. Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly. Leukemia and Lymphoma 2009, 50(March (3)):335-340.
29. Feng W.H., Cohen J.I., Fischer S., Li L., Sneller M., Goldbach-Mansky R., et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. Journal of the National Cancer Institute 2004, 96(November (22)):1691-1702.
30. Dupuis J., Boye K., Martin N., Copie-Bergman C., Plonquet A., Fabiani B., et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. American Journal of Surgical Pathology 2006, 30(April (4)):490-494.
31. Tan B.T., Warnke R.A., Arber D.A. The frequency of B- and T-cell gene rearrangements and Epstein--Barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations. Journal of Molecular Diagnostics 2006, 8(September (8)):466-475.
32. Staal S.P., Ambinder R., Beschorner W.E., Hayward G.S., Mann R. A survey of Epstein-Barr virus DNA in lymphoid tissue. Frequent detection in Hodgkin's disease. American Journal of Clinical Pathology 1989, 91(January (1)):1-5.
33. Knecht H., Sahli R., Shaw P., Meyer C., Bachmann E., Odermatt B.F., et al. Detection of Epstein-Barr virus DNA by polymerase chain reaction in lymph node biopsies from patients with angioimmunoblastic lymphadenopathy. British Journal of Haematology 1990, 75(August (4)):610-614.
34. Chan A.C., Ho J.W., Chiang A.K., Srivastava G. Phenotypic and cytotoxic characteristics of peripheral T-cell and NK-cell lymphomas in relation to Epstein-Barr virus association. Histopathology 1999, 34(January (1)):16-24.
35. Quintanilla-Martinez L., Lome-Maldonado C., Ott G., Gschwendtner A., Gredler E., Angeles-Angeles A., et al. Primary intestinal non-Hodgkin's lymphoma and Epstein-Barr virus: high frequency of EBV-infection in T-cell lymphomas of Mexican origin. Leukemia and Lymphoma 1998, 30(June (1-2)):111-121.
36. de Bruin P.C., Jiwa N.M., Oudejans J.J., Radaszkiewicz T., Meijer C.J. Epstein-Barr virus in primary gastrointestinal T cell lymphomas. Association with gluten-sensitive enteropathy, pathological features, and immunophenotype. American Journal of Pathology 1995, April (4)(146):861-867.
37. Ohshima K., Haraoka S., Harada N., Kamimura T., Suzumiya J., Kanda M., et al. Hepatosplenic gammadelta T-cell lymphoma: relation to Epstein-Barr virus and activated cytotoxic molecules. Histopathology 2000, 36(February (2)):127-135.
38. Arnulf B., Copie-Bergman C., Delfau-Larue M.H., Lavergne-Slove A., Bosq J., Wechsler J., et al. Nonhepatosplenic gammadelta T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization. Blood 1998, 91(March (5)):1723-1731.
39. Quintanilla-Martinez L., Kumar S., Fend F., Reyes E., Teruya-Feldstein J., Kingma D.W., et al. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood 2000, 96(July (2)):443-451.
40. Kim Y.C., Yang W.I., Lee M.G., Kim S.N., Cho K.H., Lee S.J., et al. Epstein-Barr virus in CD30 anaplastic large cell lymphoma involving the skin and lymphomatoid papulosis in South Korea. International Journal of Dermatology 2006, 45(November (11)):1312-1316.
41. Chan J., Wong K.F., Jaffe E.S., Ralfkiaer E. Aggressive NK-Cell Leukemia. World Health Organization classification of tumors Pathology and Genetics, Tumours of Haematopoietic and Lymphoid Tissue 2001, IARC Press, Lyon, France.
42. Harabuchi Y., Yamanaka N., Kataura A., Imai S., Kinoshita T., Mizuno F., et al. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 1990, 335(January (8682)):128-130.
43. Ho F.C., Srivastava G., Loke S.L., Fu K.H., Leung B.P., Liang R., et al. Presence of Epstein-Barr virus DNA in nasal lymphomas of B and 'T' cell type. Hematological Oncology 1990, 8(September (5)):271-281.
44. Rudiger T., Weisenburger D.D., Anderson J.R., Armitage J.O., Diebold J., MacLennan K.A., et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin's lymphoma classification project. Annals of Oncology 2002, 13(January (1)):140-149.
45. Ballester B., Ramuz O., Gisselbrecht C., Doucet G., Loi L., Loriod B., et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene 2006, 25(March (10)):1560-1570.
46. Dorfman D.M., Brown J.A., Shahsafaei A., Freeman G.J. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. American Journal of Surgical Pathology 2006, 30(July (7)):802-810.
47. Jaffe E.S., Krenacs L., Raffeld M. Classification of T-cell and NK-cell neoplasms based on the REAL classification. Annals of Oncology 1997, 8(Suppl. 2):17-24.
48. Belhadj K., Reyes F., Farcet J.P., Tilly H., Bastard C., Angonin R., et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003, 102(December (13)):4261-4269.
49. Taguchi A., Miyazaki M., Sakuragi S., Shinohara K., Kamei T., Inoue Y. Gamma/delta T cell lymphoma. Internal Medicine 2004, 43(February (2)):120-125.
50. Thorley-Lawson D.A., Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. New England Journal of Medicine 2004, 350(March (13)):1328-1337.
51. Klein G., Klein E., Kashuba E. Interaction of Epstein-Barr virus (EBV) with human B-lymphocytes. Biochemical and Biophysical Research Communications 2010, 396(May (1)):67-73.
52. Sinclair A.J., Palmero I., Peters G., Farrell P.J. EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO Journal 1994, 13(July (14)):3321-3328.
53. Calderwood M.A., Lee S., Holthaus A.M., Blacklow S.C., Kieff E., Johannsen E. Epstein-Barr virus nuclear protein 3C binds to the N-terminal (NTD) and beta trefoil domains (BTD) of RBP/CSL; only the NTD interaction is essential for lymphoblastoid cell growth. Virology 2011, 414(May (1)):19-25.
54. Knight J.S., Sharma N., Robertson E.S. SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. Molecular and Cellular Biology 2005, 25(March (5)):1749-1763.
55. Knight J.S., Sharma N., Robertson E.S. Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(December (51)):18562-18566.
56. Qiu J., Cosmopoulos K., Pegtel M., Hopmans E., Murray P., Middeldorp J., et al. A novel persistence associated EBV miRNA expression profile is disrupted in neoplasia. PLoS Pathogens 2011, 7(August (8)):e1002193.
57. Allan G.J., Inman G.J., Parker B.D., Rowe D.T., Farrell P.J. Cell growth effects of Epstein-Barr virus leader protein. Journal of General Virology 1992, 73(June (Pt 6)):1547-1551.
58. Dawson C.W., Port R.J., Young L.S. The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Seminars in Cancer Biology 2012, 22(April (2)):144-153.
59. Wang D., Liebowitz D., Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985, 43(December (3 Pt 2)):831-840.
60. Cahir McFarland E.D., Izumi K.M., Mosialos G. Epstein-barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kappaB. Oncogene 1999, 18(November (49)):6959-6964.
61. Wang F., Gregory C., Sample C., Rowe M., Liebowitz D., Murray R., et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. Journal of Virology 1990, 64(May (5)):2309-2318.
62. Gregory C.D., Dive C., Henderson S., Smith C.A., Williams G.T., Gordon J., et al. Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature 1991, 349(February (6310)):612-614.
63. Webster-Cyriaque J., Middeldorp J., Raab-Traub N. Hairy leukoplakia: an unusual combination of transforming and permissive Epstein-Barr virus infections. Journal of Virology 2000, 74(August (16)):7610-7618.
64. Raab-Traub N. Novel mechanisms of EBV-induced oncogenesis. Current Opinion in Virology 2012, 2(August (4)):453-458.
65. Young L.S., Murray P.G. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 2003, 22(August (33)):5108-5121.
66. Levitskaya J., Sharipo A., Leonchiks A., Ciechanover A., Masucci M.G. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(November (23)):12616-12621.
67. Mukherjee S., Trivedi P., Dorfman D.M., Klein G., Townsend A. Murine cytotoxic T lymphocytes recognize an epitope in an EBNA-1 fragment, but fail to lyse EBNA-1-expressing mouse cells. Journal of Experimental Medicine 1998, 187(February (3)):445-450.
68. Smith C., Cooper L., Burgess M., Rist M., Webb N., Lambley E., et al. Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope. Journal of Immunology 2006, 177(October (7)):4897-4906.
69. Jones K., Nourse J.P., Morrison L., Nguyen-Van D., Moss D.J., Burrows S.R., et al. Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders. Blood 2010, 116(September (13)):2245-2252.
70. Edwards R.H., Sitki-Green D., Moore D.T., Raab-Traub N. Potential selection of LMP1 variants in nasopharyngeal carcinoma. Journal of Virology 2004, 78(January (2)):868-881.
71. Gottschalk S., Ng C.Y., Perez M., Smith C.A., Sample C., Brenner M.K., et al. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001, 97(February (4)):835-843.
72. Frisan T., Sjoberg J., Dolcetti R., Boiocchi M., De R., Carbone V.A., et al. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 1995, 86(August (4)):1493-1501.
73. Dukers D.F., Meij P., Vervoort M.B., Vos W., Scheper R.J., Meijer C.J., et al. Direct immunosuppressive effects of EBV-encoded latent membrane protein 1. Journal of Immunology 2000, 165(July (2)):663-670.
74. Eliopoulos A.G., Stack M., Dawson C.W., Kaye K.M., Hodgkin L., Sihota S., et al. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. Oncogene 1997, 14(June (24)):2899-2916.
75. Lambert S.L., Martinez O.M. Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10. Journal of Immunology 2007, 179(December (12)):8225-8234.
76. Eliopoulos A.G., Gallagher N.J., Blake S.M., Dawson C.W., Young L.S. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. Journal of Biological Chemistry 1999, 274(June (23)):16085-16096.
77. Ouyang J., Juszczynski P., Rodig S.J., Green M.R., O'Donnell E., Currie T., et al. Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood 2011, 117(April (16)):4315-4322.
78. Toscano M.A., Bianco G.A., Ilarregui J.M., Croci D.O., Correale J., Hernandez J.D., et al. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nature Immunology 2007, 8(August (8)):825-834.
79. Ilarregui J.M., Croci D.O., Bianco G.A., Toscano M.A., Salatino M., Vermeulen M.E., et al. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nature Immunology 2009, 10(September (9)):981-991.
80. Green M.R., Rodig S., Juszczynski P., Ouyang J., Sinha P., O'Donnell E., et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clinical Cancer Research 2012, 18(March (6)):1611-1618.
81. Juszczynski P., Ouyang J., Monti S., Rodig S.J., Takeyama K., Abramson J., et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(August (32)):13134-13139.
82. Xia T., O'Hara A., Araujo I., Barreto J., Carvalho E., Sapucaia J.B., et al. EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Research 2008, 68(March (5)):1436-1442.
83. Thorley-Lawson D.A., Allday M.J. The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nature Reviews Microbiology 2008, 6(December (12)):913-924.
84. Kelly G.L., Milner A.E., Tierney R.J., Croom-Carter D.S., Altmann M., Hammerschmidt W., et al. Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis. Journal of Virology 2005, 79(August (16)):10709-10717.
85. Allday M.J. How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma?. Seminars in Cancer Biology 2009, 19(December (6)):366-376.
86. Cherney B.W., Bhatia K.G., Sgadari C., Gutierrez M.I., Mostowski H., Pike S.E., et al. Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells. Cancer Research 1997, 57(June (12)):2508-2515.
87. Zindy F., Eischen C.M., Randle D.H., Kamijo T., Cleveland J.L., Sherr C.J., et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes and Development 1998, 12(August (15)):2424-2433.
88. Eischen C.M., Weber J.D., Roussel M.F., Sherr C.J., Cleveland J.L. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes and Development 1999, 13(October (20)):2658-2669.
89. Lindstrom M.S., Wiman K.G. Role of genetic and epigenetic changes in Burkitt lymphoma. Seminars in Cancer Biology 2002, 12(October (5)):381-387.
90. Nagy N., Klein G., Klein E. To the genesis of Burkitt lymphoma: regulation of apoptosis by EBNA-1 and SAP may determine the fate of Ig-myc translocation carrying B lymphocytes. Seminars in Cancer Biology 2009, 19(December (6)):407-410.
91. Saridakis V., Sheng Y., Sarkari F., Holowaty M.N., Shire K., Nguyen T., et al. Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization. Molecular Cell 2005, 18(April (1)):25-36.
92. Komano J., Maruo S., Kurozumi K., Oda T., Takada K. Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. Journal of Virology 1999, 73(December (12)):9827-9831.
93. Yamamoto N., Takizawa T., Iwanaga Y., Shimizu N., Yamamoto N. Malignant transformation of B lymphoma cell line BJAB by Epstein-Barr virus-encoded small RNAs. FEBS Letters 2000, 484(November (2)):153-158.
94. Kelly G.L., Long H.M., Stylianou J., Thomas W.A., Leese A., Bell A.I., et al. An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathogens 2009, 5(March (3)):e1000341.
95. Anderton E., Yee J., Smith P., Crook T., White R.E., Allday M.J. Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene 2008, 27(January (4)):421-433.
96. Paschos K., Smith P., Anderton E., Middeldorp J.M., White R.E., Allday M.J. Epstein-Barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathogens 2009, 5(June (6)):e1000492.
97. Enders A., Bouillet P., Puthalakath H., Xu Y., Tarlinton D.M., Strasser A. Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells. Journal of Experimental Medicine 2003, 198(October (7)):1119-1126.
98. Fischer S.F., Bouillet P., O'Donnell K., Light A., Tarlinton D.M., Strasser A. Proapoptotic BH3-only protein Bim is essential for developmentally programmed death of germinal center-derived memory B cells and antibody-forming cells. Blood 2007, 110(December (12)):3978-3984.
99. Cross J.R., Postigo A., Blight K., Downward J. Viral pro-survival proteins block separate stages in Bax activation but changes in mitochondrial ultrastructure still occur. Cell Death and Differentiation 2008, 15(June (6)):997-1008.
100. Kvansakul M., Wei A.H., Fletcher J.I., Willis S.N., Chen L., Roberts A.W., et al. Structural basis for apoptosis inhibition by Epstein-Barr virus BHRF1. PLoS Pathogens 2010, 6(12):e1001236.
101. Puglielli M.T., Woisetschlaeger M., Speck S.H. oriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines. Journal of Virology 1996, 70(September (9)):5758-5768.
102. Tsimbouri P., Drotar M.E., Coy J.L., Wilson J.B. bcl-xL and RAG genes are induced and the response to IL-2 enhanced in EmuEBNA-1 transgenic mouse lymphocytes. Oncogene 2002, 21(August (33)):5182-5187.
103. Kube D., Vockerodt M., Weber O., Hell K., Wolf J., Haier B., et al. Expression of Epstein-Barr virus nuclear antigen 1 is associated with enhanced expression of CD25 in the Hodgkin cell line L428. Journal of Virology 1999, 73(February (2)):1630-1636.
104. Gruhne B., Sompallae R., Marescotti D., Kamranvar S.A., Gastaldello S., Masucci M.G. The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(February (7)):2313-2318.
105. Samanta M., Iwakiri D., Takada K. Epstein-Barr virus-encoded small RNA induces IL-10 through RIG-I-mediated IRF-3 signaling. Oncogene 2008, 27(July (30)):4150-4160.
106. Cerimele F., Battle T., Lynch R., Frank D.A., Murad E., Cohen C., et al. Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(January (1)):175-179.
107. Onnis A., Navari M., Antonicelli G., Morettini F., Mannucci S., De F.G., et al. Epstein-Barr nuclear antigen 1 induces expression of the cellular microRNA hsa-miR-127 and impairing B-cell differentiation in EBV-infected memory B cells. New insights into the pathogenesis of Burkitt lymphoma. Blood Cancer Journal 2012, 2:e84.
108. De F.G., Antonicelli G., Onnis A., Lazzi S., Bellan C., Leoncini L. Role of EBV in microRNA dysregulation in Burkitt lymphoma. Seminars in Cancer Biology 2009, 19(December (6)):401-406.
109. Leucci E., Onnis A., Cocco M., De F.G., Imperatore F., Giuseppina A., et al. B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression. International Journal of Cancer 2010, 126(March (6)):1316-1326.
110. Greisman H.A., Lu Z., Tsai A.G., Greiner T.C., Yi H.S., Lieber M.R. IgH partner breakpoint sequences provide evidence that AID initiates t(11;14) and t(8;14) chromosomal breaks in mantle cell and Burkitt lymphomas. Blood 2012, 120(October (14)):2864-2867.
111. Rainey J.J., Mwanda W.O., Wairiumu P., Moormann A.M., Wilson M.L., Rochford R. Spatial distribution of Burkitt's lymphoma in Kenya and association with malaria risk. Tropical Medicine and International Health 2007, 12(August (8)):936-943.
112. Potup P., Kumsiri R., Kano S., Kalambaheti T., Looareesuwan S., Troye-Blomberg M., et al. Blood stage Plasmodium falciparum antigens induce immunoglobulin class switching in human enriched B cell culture. Southeast Asian Journal of Tropical Medicine and Public Health 2009, 40(July (4)):651-664.
113. Simone O., Bejarano M.T., Pierce S.K., Antonaci S., Wahlgren M., Troye-Blomberg M., et al. TLRs innate immunereceptors and Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) CIDR1alpha-driven human polyclonal B-cell activation. Acta Tropica 2011, 119(August (2-3)):144-150.
114. Chene A., Donati D., Guerreiro-Cacais A.O., Levitsky V., Chen Q., Falk K.I., et al. A molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathogens 2007, 3(June (6)):e80.
115. Donati D., Mok B., Chene A., Xu H., Thangarajh M., Glas R., et al. Increased B cell survival and preferential activation of the memory compartment by a malaria polyclonal B cell activator. Journal of Immunology 2006, 177(September (5)):3035-3044.
116. Donati D., Zhang L.P., Chene A., Chen Q., Flick K., Nystrom M., et al. Identification of a polyclonal B-cell activator in Plasmodium falciparum. Infection and Immunity 2004, 72(September (9)):5412-5418.
117. Navarro A., Gaya A., Martinez A., Urbano-Ispizua A., Pons A., Balague O., et al. MicroRNA expression profiling in classic Hodgkin lymphoma. Blood 2008, 111(March (5)):2825-2832.
118. Contreras-Brodin B.A., Anvret M., Imreh S., Altiok E., Klein G., Masucci M.G. B cell phenotype-dependent expression of the Epstein-Barr virus nuclear antigens EBNA-2 to EBNA-6: studies with somatic cell hybrids. Journal of General Virology 1991, 72(December (Pt 12)):3025-3033.
119. Rasul A.E., Nagy N., Sohlberg E., Adori M., Claesson H.E., Klein G., et al. Simultaneous detection of the two main proliferation driving EBV encoded proteins, EBNA-2 and LMP-1 in single B cells. Journal of Immunological Methods 2012, 385(November (1-2)):60-70.
120. Kuppers R. New insights in the biology of Hodgkin lymphoma. Hematology. American Society of Hematology. Education Program 2012, 2012:328-334.
121. Kis L.L., Nishikawa J., Takahara M., Nagy N., Matskova L., Takada K., et al. In vitro EBV-infected subline of KMH2, derived from Hodgkin lymphoma, expresses only EBNA-1, while CD40 ligand and IL-4 induce LMP-1 but not EBNA-2. International Journal of Cancer 2005, 113(March (6)):937-945.
122. Dolcetti R. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders. Autoimmunity Reviews 2007, 7(December (2)):96-101.
123. Guidoboni M., Ponzoni M., Caggiari L., Lettini A.A., Vago L., De R.V., et al. Latent membrane protein 1 deletion mutants accumulate in reed-sternberg cells of human immunodeficiency virus-related Hodgkin's lymphoma. Journal of Virology 2005, 79(February (4)):2643-2649.
124. Kingma D.W., Weiss W.B., Jaffe E.S., Kumar S., Frekko K., Raffeld M. Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus--associated lymphoproliferative disorders and malignant lymphomas. Blood 1996, 88(July (1)):242-251.
125. Zuercher E., Butticaz C., Wyniger J., Martinez R., Battegay M., Boffi El A.E., et al. Genetic diversity of EBV-encoded LMP1 in the Swiss HIV cohort study and implication for NF-Kappab activation. PLoS ONE 2012, 7(2):e32168.
126. Dutton A., Woodman C.B., Chukwuma M.B., Last J.I., Wei W., Vockerodt M., et al. Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells. Blood 2007, 109(March (6)):2597-2603.
127. Roberts M.L., Cooper N.R. Activation of a ras-MAPK-dependent pathway by Epstein-Barr virus latent membrane protein 1 is essential for cellular transformation. Virology 1998, 240(January (1)):93-99.
128. Gires O., Kohlhuber F., Kilger E., Baumann M., Kieser A., Kaiser C., et al. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO Journal 1999, 18(June (11)):3064-3073.
129. Nie L., Xu M., Vladimirova A., Sun X.H. Notch-induced E2A ubiquitination and degradation are controlled by MAP kinase activities. EMBO Journal 2003, 22(November (21)):5780-5792.
130. Jundt F., Acikgoz O., Kwon S.H., Schwarzer R., Anagnostopoulos I., Wiesner B., et al. Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma. Leukemia 2008, 22(August (8)):1587-1594.
131. Smith E.M., Akerblad P., Kadesch T., Axelson H., Sigvardsson M. Inhibition of EBF function by active Notch signaling reveals a novel regulatory pathway in early B-cell development. Blood 2005, 106(September (6)):1995-2001.
132. Mathas S., Janz M., Hummel F., Hummel M., Wollert-Wulf B., Lusatis S., et al. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nature Immunology 2006, 7(February (2)):207-215.
133. Ushmorov A., Leithauser F., Sakk O., Weinhausel A., Popov S.W., Moller P., et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 2006, 107(March (6)):2493-2500.
134. Anderson L.J., Longnecker R. Epstein-Barr virus latent membrane protein 2A exploits Notch1 to alter B-cell identity in vivo. Blood 2009, 113(January (1)):108-116.
135. Flavell J.R., Baumforth K.R., Wood V.H., Davies G.L., Wei W., Reynolds G.M., et al. Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. Blood 2008, 111(January (1)):292-301.
136. Liu T.Y., Wu S.J., Huang M.H., Lo F.Y., Tsai M.H., Tsai C.H., et al. EBV-positive Hodgkin lymphoma is associated with suppression of p21cip1/waf1 and a worse prognosis. Molecular Cancer 2010, 9:32.
137. Aozasa K., Zaki M.A. Epidemiology and pathogenesis of nasal NK/T-cell lymphoma: a mini-review. ScientificWorld Journal 2011, 11:422-428.
138. Minarovits J., Hu L.F., Imai S., Harabuchi Y., Kataura A., Minarovits-Kormuta S., et al. Clonality, expression and methylation patterns of the Epstein-Barr virus genomes in lethal midline granulomas classified as peripheral angiocentric T cell lymphomas. Journal of General Virology 1994, 75(January (Pt 1)):77-84.
139. Chiang A.K., Tao Q., Srivastava G., Ho F.C., Nasal N.K. T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. International Journal of Cancer 1996, 68(November (3)):285-290.
140. Takahara M., Kis L.L., Nagy N., Liu A., Harabuchi Y., Klein G., et al. Concomitant increase of LMP1 and CD25 (IL-2-receptor alpha) expression induced by IL-10 in the EBV-positive NK lines SNK6 and KAI3. International Journal of Cancer 2006, 119(December (12)):2775-2783.
141. Fox C.P., Haigh T.A., Taylor G.S., Long H.M., Lee S.P., Shannon-Lowe C., et al. A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood 2010, 116(November (19)):3695-3704.
142. Kanemitsu N., Isobe Y., Masuda A., Momose S., Higashi M., Tamaru J., et al. Expression of Epstein-Barr virus-encoded proteins in extranodal NK/T-cell Lymphoma, nasal type (ENKL): differences in biologic and clinical behaviors of LMP1-positive and -negative ENKL. Clinical Cancer Research 2012, 18(April (8)):2164-2172.
143. Kim K., Ryu K., Ko Y., Park C. Effects of nuclear factor-kappaB inhibitors and its implication on natural killer T-cell lymphoma cells. British Journal of Haematology 2005, 131(October (1)):59-66.
144. Jeon Y.K., Kim H., Park S.O., Choi H.Y., Kim Y.A., Park S.S., et al. Resistance to Fas-mediated apoptosis is restored by cycloheximide through the downregulation of cellular FLIPL in NK/T-cell lymphoma. Laboratory Investigation 2005, 85(July (7)):874-884.
145. Ng S.B., Selvarajan V., Huang G., Zhou J., Feldman A.L., Law M., et al. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. Journal of Pathology 2011, 223(March (4)):496-510.
146. Yamanaka Y., Tagawa H., Takahashi N., Watanabe A., Guo Y.M., Iwamoto K., et al. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood 2009, 114(October (15)):3265-3275.
147. Paik J.H., Jang J.Y., Jeon Y.K., Kim W.Y., Kim T.M., Heo D.S., et al. MicroRNA-146a downregulates NFkappaB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma. Clinical Cancer Research 2011, 17(July (14)):4761-4771.
148. Roschewski M., Wilson W.H. EBV-associated lymphomas in adults. Best Practice and Research. Clinical Haematology 2012, 25(March (1)):75-89.
149. Garnier J.L., Cooper N.R., Cannon M.J. Low expression of CD20 and CD23 in Epstein-Barr virus-induced B cell tumors in SCID/hu mice. American Journal of Pathology 1993, 142(February (2)):353-358.
150. Busch L.K., Bishop G.A. The EBV transforming protein, latent membrane protein 1, mimics and cooperates with CD40 signaling in B lymphocytes. Journal of Immunology 1999, 162(March (5)):2555-2561.
151. Graham J.P., Moore C.R., Bishop G.A. Roles of the TRAF2/3 binding site in differential B cell signaling by CD40 and its viral oncogenic mimic, LMP1. Journal of Immunology 2009, 183(September (5)):2966-2973.
152. Vaysberg M., Lambert S.L., Krams S.M., Martinez O.M. Activation of the JAK/STAT pathway in Epstein Barr virus+-associated posttransplant lymphoproliferative disease: role of interferon-gamma. American Journal of Transplantation 2009, 9(October (10)):2292-2302.
153. Zhao B., Mar J.C., Maruo S., Lee S., Gewurz B.E., Johannsen E., et al. Epstein-Barr virus nuclear antigen 3C regulated genes in lymphoblastoid cell lines. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(January (1)):337-342.
154. Piovan E., Tosello V., Indraccolo S., Cabrelle A., Baesso I., Trentin L., et al. Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation. Blood 2005, 105(February (3)):931-939.
155. Chou Y.C., Lin S.J., Lu J., Yeh T.H., Chen C.L., Weng P.L., et al. Requirement for LMP1-induced RON receptor tyrosine kinase in Epstein-Barr virus-mediated B-cell proliferation. Blood 2011, 118(August (5)):1340-1349.
156. Gatto G., Rossi A., Rossi D., Kroening S., Bonatti S., Mallardo M. Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway. Nucleic Acids Research 2008, 36(November (20)):6608-6619.
157. Lu F., Weidmer A., Liu C.G., Volinia S., Croce C.M., Lieberman P.M. Epstein-Barr virus-induced miR-155 attenuates NF-kappaB signaling and stabilizes latent virus persistence. Journal of Virology 2008, 82(November (21)):10436-10443.
158. Lin Z., Flemington E.K. miRNAs in the pathogenesis of oncogenic human viruses. Cancer Letters 2011, 305(June (2)):186-199.
159. Forte E., Salinas R.E., Chang C., Zhou T., Linnstaedt S.D., Gottwein E., et al. The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells. Journal of Virology 2012, 86(June (12)):6889-6898.
160. Cameron J.E., Yin Q., Fewell C., Lacey M., McBride J., Wang X., et al. Epstein-Barr virus latent membrane protein 1 induces cellular MicroRNA miR-146a, a modulator of lymphocyte signaling pathways. Journal of Virology 2008, 82(February (4)):1946-1958.
161. Forte E., Luftig M.A. MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival. Journal of Virology 2009, 83(March (6)):2491-2499.
162. Cai Q., Guo Y., Xiao B., Banerjee S., Saha A., Lu J., et al. Epstein-Barr virus nuclear antigen 3C stabilizes Gemin3 to block p53-mediated apoptosis. PLoS Pathogens 2011, 7(December (12)):e1002418.
163. Saha A., Lu J., Morizur L., Upadhyay S.K., Aj M.P., Robertson E.S. E2F1 mediated apoptosis induced by the DNA damage response is blocked by EBV nuclear antigen 3C in lymphoblastoid cells. PLoS Pathogens 2012, 8(3):e1002573.
164. Hatton O., Phillips L.K., Vaysberg M., Hurwich J., Krams S.M., Martinez O.M. Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas. Journal of Biological Chemistry 2011, 286(October (43)):37368-37378.
165. Kis L.L., Salamon D., Persson E.K., Nagy N., Scheeren F.A., Spits H., et al. IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(January (2)):872-877.
166. Nagy N., Adori M., Rasul A., Heuts F., Salamon D., Ujvari D., et al. Soluble factors produced by activated CD4+ T cells modulate EBV latency. Proceedings of the National Academy of Sciences of the United States of America 2012, 109(January (5)):1512-1517.
167. Konforte D., Simard N., Paige C.J. Interleukin-21 regulates expression of key Epstein-Barr virus oncoproteins, EBNA2 and LMP1, in infected human B cells. Virology 2008, 374(April (1)):100-113.
168. Nguyen-Van D., Keane C., Han E., Jones K., Nourse J.P., Vari F., et al. Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes. American Journal of Blood Research 2011, 1(2):146-159.
169. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403(February (6769)):503-511.
170. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New England Journal of Medicine 2002, 346(June (25)):1937-1947.
171. Castillo J.J., Beltran B.E., Miranda R.N., Paydas S., Winer E.S., Butera J.N. Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far. Oncologist 2011, 16(1):87-96.
172. Montes-Moreno S., Odqvist L., Diaz-Perez J.A., Lopez A.B., de Villambrosia S.G., Mazorra F., et al. EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Modern Pathology 2012, 25(July (7)):968-982.
173. Bavi P., Uddin S., Bu R., Ahmed M., Abubaker J., Balde V., et al. The biological and clinical impact of inhibition of NF-kappaB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL). Journal of Pathology 2011, 224(July (3)):355-366.
174. Gonin J., Larousserie F., Bastard C., Picquenot J.M., Couturier J., Radford-Weiss I., et al. Epstein-Barr virus-induced gene 3 (EBI3): a novel diagnosis marker in Burkitt lymphoma and diffuse large B-cell lymphoma. PLoS ONE 2011, 6(9):e24617.
175. Vrzalikova K., Vockerodt M., Leonard S., Bell A., Wei W., Schrader A., et al. Down-regulation of BLIMP1alpha by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas. Blood 2011, 117(June (22)):5907-5917.
176. Skare J., Farley J., Strominger J.L., Fresen K.O., Cho M.S., zur H.H. Transformation by Epstein-Barr virus requires DNA sequences in the region of BamHI fragments Y and H. Journal of Virology 1985, 55(August (2)):286-297.
177. Kaye K.M., Izumi K.M., Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proceedings of the National Academy of Sciences of the United States of America 1993, 90(October (19)):9150-9154.
178. Tomkinson B., Robertson E., Kieff E. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. Journal of Virology 1993, 67(April (4)):2014-2025.
179. Humme S., Reisbach G., Feederle R., Delecluse H.J., Bousset K., Hammerschmidt W., et al. The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(September (19)):10989-10994.
180. Montone K.T., Hodinka R.L., Salhany K.E., Lavi E., Rostami A., Tomaszewski J.E. Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease. Modern Pathology 1996, 9(June (6)):621-630.
181. Xue S.A., Labrecque L.G., Lu Q.L., Ong S.K., Lampert I.A., Kazembe P., et al. Promiscuous expression of Epstein-Barr virus genes in Burkitt's lymphoma from the central African country Malawi. International Journal of Cancer 2002, 99(June (5)):635-643.
182. Hanto D.W., Frizzera G., Gajl-Peczalska K.J., Sakamoto K., Purtilo D.T., Balfour H.H., et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. New England Journal of Medicine 1982, 306(April (15)):913-918.
183. Darenkov I.A., Marcarelli M.A., Basadonna G.P., Friedman A.L., Lorber K.M., Howe J.G., et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997, 64(September (6)):848-852.
184. Hong G.K., Gulley M.L., Feng W.H., Delecluse H.J., Holley-Guthrie E., Kenney S.C. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. Journal of Virology 2005, 79(November (22)):13993-14003.
185. Khatri V.P., Baiocchi R.A., Bernstein Z.P., Caligiuri M.A. Immunotherapy with low-dose interleukin-2: rationale for prevention of immune-deficiency-associated cancer. Cancer Journal From Scientific American 1997, 3(Suppl. 1):S129-S136.
186. Haddad E., Paczesny S., Leblond V., Seigneurin J.M., Stern M., Achkar A., et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 2001, 97(March (6)):1590-1597.
187. Hong D.S., Angelo L.S., Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007, 110(November (9)):1911-1928.
188. Mahot S., Sergeant A., Drouet E., Gruffat H. A novel function for the Epstein-Barr virus transcription factor EB1/Zta: induction of transcription of the hIL-10 gene. Journal of General Virology 2003, 84(April (Pt 4)):965-974.
189. Tsai S.C., Lin S.J., Chen P.W., Luo W.Y., Yeh T.H., Wang H.W., et al. EBV Zta protein induces the expression of interleukin-13, promoting the proliferation of EBV-infected B cells and lymphoblastoid cell lines. Blood 2009, 114(July (1)):109-118.
190. Kapp U., Yeh W.C., Patterson B., Elia A.J., Kagi D., Ho A., et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. Journal of Experimental Medicine 1999, 189(June (12)):1939-1946.
191. Kimura H., Hoshino Y., Hara S., Sugaya N., Kawada J., Shibata Y., et al. Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection. Journal of Infectious Diseases 2005, 191(February (4)):531-539.
192. Aldinucci D., Lorenzon D., Olivo K., Rapana B., Gattei V. Interactions between tissue fibroblasts in lymph nodes and Hodgkin/Reed-Sternberg cells. Leukemia and Lymphoma 2004, 45(September (9)):1731-1739.
193. Pallesen G., Sandvej K., Hamilton-Dutoit S.J., Rowe M., Young L.S. Activation of Epstein-Barr virus replication in Hodgkin and Reed-Sternberg cells. Blood 1991, 78(September (5)):1162-1165.
194. Hong G.K., Kumar P., Wang L., Damania B., Gulley M.L., Delecluse H.J., et al. Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. Journal of Virology 2005, 79(November (22)):13984-13992.
195. Cayrol C., Flemington E.K. Identification of cellular target genes of the Epstein-Barr virus transactivator Zta: activation of transforming growth factor beta igh3 (TGF-beta igh3) and TGF-beta 1. Journal of Virology 1995, 69(July (7)):4206-4212.
196. Ma S.D., Hegde S., Young K.H., Sullivan R., Rajesh D., Zhou Y., et al. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. Journal of Virology 2011, 85(January (1)):165-177.
197. Bollard C.M., Rooney C.M., Heslop H.E. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nature Reviews Clinical Oncology 2012, 9(September (9)):510-519.
198. Merlo A., Turrini R., Dolcetti R., Martorelli D., Muraro E., Comoli P., et al. The interplay between EBV and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica 2010, 95(10):1769-1777.
199. Wildeman M.A., Novalic Z., Verkuijlen S.A., Juwana H., Huitema A.D., Tan I.B., et al. Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors. Clinical Cancer Research 2012, 18(18):5061-5070.